Bold Science. Life-Changing Cures.
The Campaign for Mass. Eye and Ear.
Thank you for your interest in Massachusetts Eye and Ear and our fundraising campaign: "Bold Science. Life-Changing Cures." This Campaign will be an institutional game-changer. It will infuse significant financial resources into research programs that already define the "leading edge" in vision and hearing sciences; it will further empower the most talented group of physicians and scientists ever assembled in the fields of Ophthalmology and Otolaryngology; and it will help support the facilities needed by our faculty to conduct their world-class work.
Our goal is ambitious and clear: to expedite cures for blindness, deafness and diseases of the head and neck by investing $200 million dollars in three key areas: people, programs and places (our facilities).
Led by two visionaries in their respective fields, Joan W. Miller, M.D., Chief of Ophthalmology and D. Bradley Welling, M.D., Ph.D., FACS, Chief of Otolaryngology, Mass. Eye and Ear is 127 investigators strong, an unprecedented collective of scientific firepower focused squarely on diseases of the eye, ear, nose, throat, head and neck.
Mass. Eye and Ear scientists are searching for cures on multiple fronts, from gene therapies that reverse blindness to stem-cell techniques that spawn hair cell regeneration to restore hearing. Resources from "Bold Science. Life-Changing Cures," will accelerate the pace at which discoveries move from the research bench to the patient's bedside. It will enable us to recruit and retain an ideal complement of researchers to carry forth groundbreaking research. And it will provide the tools, technologies and research space necessary for optimal productivity.
Our patients, and patients worldwide, who are hearing or visually impaired or facing life-threatening diseases like head and neck cancer, are counting on us to deliver cures. Our sense of urgency, in both our research work and in the successful completion our Campaign, must mirror theirs. Please join us in this historic undertaking.
Wyc Grousbeck, John Fernandez,
Chairman of the Board President and CEO